Research Profile

Wolverine

BPC-157 10 mg · TB-500 10 mg

Wolverine combines BPC-157 and TB-500, two investigational compounds often discussed together in the peptide marketplace. The scientific literature supports biological interest in tissue-repair pathways, but the evidence base is much stronger in cells and animal models than in controlled human trials.

View COA Contact
HELVETIC
PEPTIDES
WOLVERINE

BPC-157 research

Preclinical studies have explored angiogenesis, fibroblast activity, tendon and muscle models, gastrointestinal protection and inflammatory pathways. A 2025 review described broad preclinical support but only a handful of small, uncontrolled human pilot studies.

Thymosin beta-4 / TB-500 research

Thymosin beta-4 biology includes actin sequestration, cell migration and repair signaling. Published clinical research exists for specific thymosin beta-4 preparations in areas such as dermal and corneal repair. However, a commercial substance labeled TB-500 should not automatically be represented as equivalent to full-length thymosin beta-4 used in a particular trial.

Why the combination interests researchers

The two research areas overlap around cell migration, blood-vessel signaling, connective-tissue biology and injury-response pathways. That provides a scientific rationale for studying them together, but rationale is not the same as demonstrated combination efficacy.

Evidence limitations

There are no robust randomized human trials establishing that the BPC-157/TB-500 combination heals tendons, repairs joints, speeds athletic recovery or treats injury. Those would be therapeutic claims and go beyond the available evidence.

Research-use perspective

These summaries describe published areas of scientific investigation. They are not claims that this product diagnoses, treats, cures or prevents disease, and they do not provide dosing, reconstitution or administration instructions.